FDA issues milestone draft guidance on decentralized clinical trial design & implementation

The U.S. Food and Drug Administration (FDA) has just published a highly-anticipated draft guidance on the implementation of decentralized clinical trials (DCTs) for drugs, biologics, and medical devices. In the draft guidance, FDA promotes DCTs as a way to advance medical product development and to increase diversity in clinical trial recruitment….
By: Hogan Lovells